1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

  • July 2017
  • 136 pages
  • ID: 5057870
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Summary
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.

There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.

Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.

Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.

The report “Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis” provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In depth, this report provides the following -
- Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
- Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
- Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
- Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company’s pipeline portfolio and total revenues.

Companies mentioned in this report: Johnson & Johnson, AbbVie, Amgen, Novartis, Pfizer

Scope
- Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- What are the leading companies in terms of market share?
- Which companies are forecast to experience the largest growth in market share?
- Which companies rely heavily on revenue derived from antibacterial drugs?
- How will the market respond to recent approvals?
- Will generics and biosimilars have a significant impact on the market over the forecast period?
- What class of drugs dominate the market?
- What molecular targets are most popular in the pipeline?
- What are the commercial prospects for the most promising late-stage products?

Reasons to buy
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Dermatology Devices Market Research and Outlook, 2020- Trends, Growth Opportunities and Forecasts to 2028

  • $ 4880
  • February 2021
  • 110 pages

Dermatology Devices Market Report Overview Dermatology Devices market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and majo ...

  • World
  • Healthcare
  • Aesthetic Medical Device
  • Industry analysis
  • Health Provider Density

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on